Index Intelligence

· daily

S&P 500 Industrials Sector SEC Filings — May 06, 2026

Across 50 filings in the USA S&P 500 Industrials stream (broadly including adjacent sectors like energy, pharma, and machinery), sentiment is predominantly mixed (24/50), with 10 positive and 12 neutral/low materiality 13F snapshots; YoY revenue growth averages +20% in 18 key reporters (e.g., AMD +38%, Pattern +43%, ITT +33%), but QoQ declines prevalent in cash/assets (e.g., 8/15 showed -10%+ cash drops) and margins compressed in 7/12 (avg -150bps). Net income surged in outperformers like Parke Bancorp (+52% YoY), SandRidge (+44%), GEO (+96%), but biotechs/pharma (12 filings) reported widened losses from R&D spikes (e.g., Mirum +$775M net loss). Capital allocation bullish: 10 companies hiked dividends/buybacks (e.g., SandRidge +8%, ITT $0.386/share), 5 M&A/deals (e.g., Fresh Del Monte $308M acquisition). Guidance raised in 9/15 (e.g., Pattern +32%, LandBridge $210-230M EBITDA), signaling momentum; portfolio trend: Industrials/energy outperform biotechs on profitability. Implications: Tactical buys in growth industrials (ITT, JCI), caution on cash-burn biotechs; alpha from catalysts like Phase 3 readouts H2 2026.

15 high priority 35 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — May 06, 2026

Across 17 filings in the USA S&P 500 Energy intelligence stream (with energy-relevant subset including Devon, APA, Chesapeake Utilities, Dorchester Minerals, Hallador Energy, ONEOK), Q1 2026 results show mixed performance: producers like Devon (-14% YoY revenue, -76% net earnings) and Hallador (-13.5% revenue, net loss vs profit) faced headwinds from lower oil/gas/NGL sales and electric volumes, while royalties (Dorchester +36% revenue, +65% net income) and utilities (Chesapeake +18.3% revenue, +16.5% net income) outperformed on volume growth and regulatory tailwinds. APA raised full-year US oil production guidance to 122k bbl/d amid cost savings progress toward $450M, and Hallador secured a 12-year $1B+ capacity deal doubling forward book. Capital allocation trends favor shareholder returns (Dorchester distribution +2% YoY per unit, Chesapeake dividends +7% YoY) and deleveraging (Hallador bank debt to $0, APA repaid $634M bonds). Institutional 13Fs (HughesLittle, Westchester, Copeland) provide neutral snapshots with no major energy shifts. Non-energy filings (Papa Johns mixed AGM votes, Williams Sonoma strong proxy TSR) signal broader market governance focus. Portfolio implication: rotate to resilient midstream/royalties amid E&P volatility, watch Q2 catalysts for guidance updates.

7 high priority 10 medium 17 total filings
· daily

Dow Jones 30 Stocks SEC Filings — May 06, 2026

The 50 pre-analyzed SEC filings for USA Dow Jones 30 stream reveal a resilient Q1 2026 earnings season with 18/25 quarterly reporters showing YoY revenue growth averaging +28% (range 4%-108%, led by Viper Energy +108% and Lumentum +90%), though profitability is mixed with 12/25 net income declines averaging -25% due to margin compression (-150bps avg in 8 cases) from rising costs, special charges, and op expenses. Capital allocation remains shareholder-friendly, with 14 companies announcing/declaring dividends (e.g., Acushnet $0.255/share, Flowco +12.5% to $0.09) and 10 executing buybacks totaling ~$300M (e.g., Ingevity $52M, Life Time $62.7M). M&A activity heats up with positive updates on Skyworks-Qorvo (Phase II China review, $500M synergies), Two Harbors-CCM ($11.30/share, Q3 close), and Clear Channel take-private ($2.43/share, vote May 12). Guidance raised in 5 cases (CVS Adjusted EPS $7.30-7.50, LivaNova $4.20-4.30), reaffirmed in 6, signaling cautious optimism; 13F filings show institutional tilt to tech megacaps (NVIDIA, Apple, Amazon topping 8/10 portfolios). Sector patterns highlight energy/materials outperformance vs. manufacturing/construction weakness, with portfolio-level trend of deposit/asset contractions in banks (Parke -2% assets QoQ) but robust cash flows in tech/healthcare. Key implications: Favor growth names with raised guidance and buybacks for near-term upside, monitor M&A catalysts and margin trends for volatility.

20 high priority 30 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — May 06, 2026

Across 50 SEC filings from the S&P 500 Consumer Discretionary stream (primarily retail, automotive, restaurants, hotels, entertainment), sentiment is predominantly mixed with 14/25 detailed financial reporters showing YoY revenue growth averaging +12% (e.g., YUM Brands +15%, Marriott RevPAR +4.2%), but margins compressed in 7/15 cases by avg -150 bps amid higher expenses and impairments. Capital allocation remains shareholder-friendly with $1.5B+ in buybacks/dividends (Marriott $0.7B repurchases, SandRidge dividend +8%, Life Time $62M buyback), while M&A activity accelerates (Fresh Del Monte $307M acquisition, Nuveen $347M asset purchase). Forward guidance mixed: 5 raises (Freshpet to 8-11% sales growth) vs 4 cuts (Louisiana-Pacific Siding -2% FY2026). 13F filings reveal institutional conviction in tech-discretionary overlap (Apple/NVIDIA top holdings in multiple). Key theme: Resilience in hospitality/foodservice vs cyclical pressures in building/produce; portfolio implication: overweight restaurants/hotels, underweight commodities-exposed names.

24 high priority 26 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — May 06, 2026

Across 50 SEC filings from the USA S&P 500 Healthcare stream (primarily pharmaceuticals, biotech, med devices, providers, with some cross-sector), Q1 2026 results reveal mixed performance: 12/18 reporting companies showed YoY revenue growth averaging +18% (led by BeOne Medicines +35%, CoreCivic +25.8%, CVS +6.2%), but 6 experienced declines averaging -15% (e.g., Castle Biosciences -5%, Louisiana-Pacific -21%). Margin trends are divergent with improvements in 7 firms (e.g., Castle gross margin +24pts to 73%, BeOne +4pts to 89%) offset by compressions in 5 (e.g., Edgewell -410bps, Green Thumb -340bps). Guidance was raised by 9 companies (e.g., BeOne FY rev to $6.3-6.5B, CVS Adj EPS $7.30-7.50), signaling optimism amid capex surges and buybacks ($200M+ returned across firms like News Corp $1B program, Chime $200M auth). Capital allocation favors returns (dividends doubled at Atmos, NVE $1.00/shr) over reinvestment, with M&A active (Corebridge-Equitable synergies, CoreCivic $148M acquisition). Biotech catalysts dominate (Revolution Medicines Ph3 success, Sight Sciences $55M patent win), but leadership changes (Anavex CEO exit) and expense inflation pose risks. Portfolio implication: overweight high-growth biopharma with raised guidance, monitor med device margin pressures.

17 high priority 33 medium 50 total filings
· daily

S&P 500 Financials Sector SEC Filings — May 05, 2026

Across 50 SEC filings dated May 5, 2026, primarily Q1 2026 earnings and corporate actions, mixed sentiment dominates (65% of filings), with revenue growth averaging +10% YoY in 25 reporters (e.g., Ecovyst +50%, Terex +41%, Paymentus +30%) offset by margin compressions in 15 cases (avg -200bps, e.g., Atkore -780bps) due to costs, impairments, and one-offs. Financials subset (e.g., bank 0000083246 NI +45% YoY, Oaktree BDC income -9% QoQ) shows improving credit provisions (-59% YoY) but deposit/loan pressures. Capital allocation prioritizes returns: $1.8B+ in buybacks/ASRs (Gartner $535M +$600M auth, DuPont $275M, Five9 $90M, Ecovyst $35.7M) and dividends (e.g., Atkore $0.33, Fresh Del Monte $0.30). M&A/divestitures active for focus/delevering (Compass $280M proceeds targeting <1.0x leverage, Helix $107.5M sale, Expro $215M acq). Guidance raised in 8/15 cases (DuPont EPS $2.35-2.40, ADM $4.15-4.70, Ecovyst EBITDA $180-195M), signaling resilience amid macro challenges. SPAC IPOs (CH4 $200M, ARC $105M) highlight M&A appetite. Portfolio implication: Favor capital returners with raised guidance; monitor margin trends and merger closes.

17 high priority 33 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — May 05, 2026

Across 50 SEC filings from S&P 500 Industrials and related sectors for Q1 2026, mixed sentiment prevails in 70% of reports, driven by robust revenue growth in 25 companies (avg +12% YoY, e.g., Eaton +17%, IDEXX +14%) offset by margin pressures (avg -80 bps in 15 firms) and segment declines. Acquisitions dominate capital allocation with $25B+ deployed (Eaton $11B, Waters BD unit), boosting assets but spiking debt (Eaton LT debt +112% to $18.5B). Guidance raised in 12 firms (e.g., Eaton organic 9-11%, Waters rev $6.4-6.45B), signaling conviction amid Aerospace/Electrical strength (+16-21% YoY). Dividend hikes (Sunoco +6.25%, Ferguson $0.89) and buybacks (Dave 7% shares, DuPont $275M ASR) highlight shareholder returns totaling $3B+. Insider patterns limited, but proxy votes (Lattice 95-98% director approval) show alignment; M&A catalysts cluster in Q2-Q3. Portfolio trend: Industrials outpace REITs/pharma with 8/10 revenue beaters, but watch debt leverage (avg 3.5x up 20% YoY in acquirers). Actionable: Favor electrical/aerospace growers, trim high-debt REITs pre-mergers.

9 high priority 41 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — May 05, 2026

S&P 500 Energy sector filings highlight robust upstream production growth and consolidation via Devon Energy's shareholder-approved merger with Coterra (close ~May 7, 2026, $1B synergies by 2027), alongside mixed Q1 2026 results: EOG Resources led with +27% YoY total production to 1,384 MBoed, +22% revenues to $6.9B, and +30% CFO to $3.0B, while Marathon Petroleum swung to $511M net income (+$585M YoY) on refining margins +$4.36/bbl to $17.74 but midstream EBITDA -7% to $1.6B. Occidental Petroleum showed one-time gains from OxyChem sale boosting net income to $3.2B but continuing ops income -72% YoY to $236M and sales -8% amid debt reduction to $13.3B toward $10B target. Capital returns remain strong with MPC's new $5B buyback, EOG dividends +5% to $1.02/share, and Devon FCF $816M; however, cost pressures (EOG op ex +13%, MPC refining costs +8%) signal margin risks. Neutral 13F filings from Williams Jones and Duncan Williams show no major energy shifts, while non-core filings (CommScope M&A, Real Brokerage merger comms) add minimal sector alpha. Portfolio-level: 4/4 key energy cos reported production beats or guidance tops, but refining/midstream mixed, pointing to upstream outperformance amid consolidation.

5 high priority 8 medium 13 total filings
· daily

Nasdaq 100 Stocks SEC Filings — May 04, 2026

Across 30 SEC filings from NASDAQ-100 related entities on May 4, 2026, overarching themes include mixed Q1 2026 financial results with revenue growth in niche players (e.g., OneMeta +4710% YoY, Metallus +10% YoY) offset by declines in established names (Cogent service rev -3.2% YoY, Apple Hospitality net income -11.3% YoY), strong shareholder approvals at annual meetings (Gilead, Intuitive Surgical, Cogent >90% FOR on key proposals), and active capital markets with Meta's $25B debt raise and Genco's $23.50/share tender offer. Portfolio-level trends show margin resilience in some (Cogent EBITDA margin + to 29.3%, Metallus EBITDA +39% YoY) amid operating losses, with REITs like Apple Hospitality and Sun Communities signaling acquisition pipelines and presentations. M&A/SPAC activity is elevated (AParadise merger approval with 19.6M shares redeemed, Genco takeover), while capital allocation favors buybacks/dividends (Apple Hospitality $242.5M remaining, Cogent $0.02 dividend). Neutral 13F filings indicate passive institutional holding, and positive governance updates (board appointments, equity plans) dominate. Implications: Selective growth opportunities in high-flyers, caution on margin pressures, catalysts from conferences and deal closings.

14 high priority 16 medium 30 total filings
· daily

S&P 500 Financials Sector SEC Filings — May 04, 2026

Across 50 SEC filings from May 4, 2026, primarily S&P 500 Financials but spanning insurers, REITs, banks, SPACs, and broader sectors, key themes include robust M&A/SPAC activity (e.g., GNL-Modiv accretive merger, multiple IPO S-1/A amendments), mixed Q1 2026 results with aggregate revenue growth of ~6% YoY in reporting companies (e.g., Berkshire +4.4%, Loews +1.4%, CNA +1.4%) but volatile net income (Berkshire +119% outlier, CNA -23%, Loews -9%), and insurance underwriting pressures (combined ratios worsening ~380bps YoY at CNA/Loews). Capital allocation shows steady dividends (CNA $0.48/share, Superior $0.14/share) amid buybacks (Berkshire $235M treasury stock) and debt reductions (Superior LT debt -8% QoQ). Institutional 13Fs reveal tech-heavy portfolios (e.g., Crystal Rock top Alphabet/Meta, Yahav QQQ semis), signaling conviction in growth sectors. Forward-looking data flags lowered guidance (Norwegian Net Yield -3-5%) and catalysts like Cabaletta data H1/H2 2026. Portfolio-level trends: 8/12 earnings reporters saw revenue +YoY but 6/12 net income declines; M&A premiums average 17% (GNL-Modiv). Implications: Favor accretive deals and strong earners like Berkshire; caution insurers on reserves/loss ratios amid positive BVPS trends.

28 high priority 22 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — May 04, 2026

Across 50 SEC filings from the USA S&P 500 Consumer Staples intelligence stream (broadly encompassing food, beverages, household, personal care with adjacent industrials/energy), overarching themes include mixed Q1 2026 earnings with revenue growth averaging +8% YoY in reporting firms (e.g., Krystal +32%, Powell +6%) but frequent profit declines (-20% avg in mixed reporters like Exxon -46%, NCL EPS double but FY guidance cut) due to cost pressures, margin compression (~150 bps avg in 7/15 metrics), and working capital strains. M&A activity surges with accretive deals like GNL-Modiv ($535M, +4% AFFO, Q3 close) and Hubbell-NSI ($3B, +EPS 2026), signaling consolidation; capital returns robust via buybacks ($66M New Mountain, $548M Diamondback) and dividends (Great Elm 18% yield, SmartStop $1.60 ann.). Portfolio-level patterns show 6/10 mixed sentiment filings with NAV declines (e.g., New Mountain -5.2%, Great Elm -4%) amid unrealized losses, but positive catalysts in FDA approvals (ADMA) and order backlogs (Powell +33% to $1.8B). Implications: Favor M&A beneficiaries and capex raisers (Diamondback oil +5% FY guide) over guidance cutters (NCL yields -3-5%); sector faces margin headwinds but strong liquidity supports returns.

23 high priority 27 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — May 04, 2026

Across 50 SEC filings from the USA S&P 500 Industrials stream (broadly encompassing aerospace, defense, machinery, transportation, construction, and adjacent sectors), overarching themes include mixed Q1 2026 earnings with 6/10 reporting companies showing revenue growth averaging +20% YoY (e.g., Biodesix +42%, Backblaze +11.7%) offset by declines in cyclicals like Boise Cascade (-2% sales YoY) and Cogent (-3.2% YoY), alongside accretive M&A in industrial real estate and positive capital raises/licensing in health-adjacent industrials. EBITDA margins expanded in 7/12 key filers (avg +200bps YoY, driven by cost controls at Boise +136% BMD EBITDA growth and Backblaze +800bps to 26%), signaling operational resilience amid softening demand from housing starts (-5% YoY). Capital allocation remains shareholder-friendly with $65.5M Boise buybacks, $548M Diamondback repurchases, and consistent dividends (e.g., Marzetti $0.12/share). Forward-looking catalysts cluster in Q2-Q3 2026, including merger closes, guidance realizations, and clinical data readouts. Institutional 13F snapshots (16/50 filings) reveal heavy tech/industrials tilts (e.g., Vertiv, BWX Tech), indicating conviction in infrastructure/AI themes. Most critical: Global Net Lease's $535M industrial acquisition (4% AFFO accretive, Q3 close) and Biodesix's 42% revenue surge with raised FY guidance, positioning select industrials for outperformance vs. sector peers.

16 high priority 34 medium 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — May 04, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream (May 4, 2026 period), dominant themes include aggressive M&A in industrial/REIT space (GNL-Modiv $535M all-stock deal, 4% AFFO accretive, 17% premium), mixed Q1 2026 earnings with pharma/biotech revenue growth averaging +7-8% YoY (Evolus +7%, Vertex +8%) offset by declines in offshore drilling (-13% QoQ Valaris) and telecom (-3.2% YoY Cogent), and robust capital allocation via buybacks/repurchases (Indivior $175M ASR, Progressive $467M treasury shares). Institutional 13Fs (14 filings) reveal heavy tech concentration (e.g., NVIDIA, Amazon top holdings across Yahav, Triglav, Montaka), signaling sustained bull market conviction. Forward-looking data flags lowered guidance (Norwegian Cruise Net Yield -3-5%, EPS $1.45-1.79) amid demand softness, contrasted by reaffirmed targets (Evolus $327-337M revenue). Bankruptcies (Safe & Green, Spirit Aviation wind-down) highlight distress in niche industrials/aviation. Portfolio-level trends: 6/12 earnings filings show YoY revenue growth >5% but 4/12 with EBITDA/affo declines; capital returns strong in 5 firms (dividends, buybacks up YoY). Actionable: M&A catalysts in Q3 2026, watch biotech data readouts H1-H2.

14 high priority 36 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — May 04, 2026

Across 50 filings in the S&P 500 Consumer Discretionary stream (with cross-sector exposure via REITs, food/retail, and industrials), sentiment is predominantly mixed (14/50), reflecting revenue growth averaging +12% YoY in 18 earnings reporters (e.g., Sterling +92%, L.B. Foster +24%, Tyson +4.4%) but offset by profitability challenges like impairments (Armada net loss worsened to $33.3M) and volume declines (FreightCar -33%, OneWater -8.5%). Guidance trends are resilient with 6 raises/reaffirmations (Armada FFO to $0.51-$0.55, Sterling EBITDA to $843-873M), signaling management conviction amid restructuring (e.g., Armada $562M portfolio sale, $700M debt paydown). Capital allocation favors shareholders via $24.1M buybacks (Armada), dividends (Tyson $0.48, Superior $0.14, SmartStop $1.60 annualized), and M&A approvals (Farmer Bros 86.9% yes). IPO activity (GMR, Liftoff, Fervo) and SPAC developments (Willow neutral, Flag Ship terminated) highlight deal flow risks/opportunities. Institutional 13Fs (11 filings) show stable heavy weighting in consumer/tech names like Costco, Amazon (e.g., Garrison top Costco $10M). Portfolio-level: Margin expansion in winners (Marzetti + to 23.6%) vs compression elsewhere; actionable now on raised guidance and near-term catalysts like May 15 Cushman redemption.

15 high priority 35 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — May 04, 2026

Across 50 filings in the USA S&P 500 Healthcare stream (with broader financial crossovers), mixed sentiment dominates healthcare/biotech names, with 4/7 key players (Twist, Vertex, Merck, Aura) showing YoY revenue growth averaging +12.8% (Twist +19%, Vertex +8%, Merck +4.9%) but widening net losses due to elevated R&D/SG&A (e.g., Twist net loss +12% YoY to $44M, Merck $4.2B loss from $8.5B acquisition charge), signaling heavy investment in pipelines amid 99% revenue plunge outlier at Akston Biosciences IPO. Capital allocation leans bullish with buybacks surging (Intuitive Surgical $5B authorization, Tidewater $500M, New Mountain $66M YTD +$50M more, Aura $39M repurchase), dividends steady (CNA $0.48, Corebridge $0.25), and share repurchases reflecting management conviction despite NAV declines (New Mountain -5.2% to $10.92). Leadership transitions positive in healthcare (Aura new CEO Natalie Holles, Edwards new CFO Doretta Mistras), while non-healthcare finance/insurance shows stable NII but margin pressures (CNA combined ratio +380bps to 102.2%, Loews net income -9%). Forward guidance largely raised/reiterated (Twist FY26 rev to $442-447M +17-19% growth, Vertex $12.95-13.1B), building H2 2026-2027 catalysts like Aura Phase 3 topline. 13F filings (9 total) reveal neutral institutional positioning with heavy ETF/tech tilts but healthcare exposure (e.g., Thermo Fisher, UnitedHealth). Portfolio-level: Healthcare growth intact but loss-making (avg gross margin +100bps at Twist), buybacks signal undervaluation, watch M&A (Corebridge-Equitable, Rallybio termination fee $50M). Actionable: Favor buyback-heavy medtech/biotech over plunging revenue IPOs.

17 high priority 33 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — May 04, 2026

Across 28 filings in the USA S&P 500 Technology stream (broadly including adjacent sectors like comms, medtech, and SPACs), Q1 2026 results show mixed trends: revenue declines in Cogent Communications (-3.2% YoY to $239M) and off-net (-17% YoY), offset by EBITDA margin expansion (+2.1% YoY to 29.3%) and wavelength surge (+90.8% YoY); Apple Hospitality REIT RevPAR +2.2% YoY but net income -11.3% YoY. Strong AGM outcomes at Intuitive Surgical (10/10 proposals passed, $5B buyback authorization) and Cogent (directors >90% FOR, CEO 1M RSU perf award) signal management alignment and conviction. SPAC activity peaks with AParadise merger approval but 19.6M share redemptions (93% of quorum), flagging dilution risks; Genco tender offer at $23.50/share adds M&A momentum. Capital allocation favors returns: Cogent $0.02/share dividend, Apple Hospitality $242.5M buyback remaining and forward hotel buys ($65.5M Q4'27, $143.7M Q2'28). 13F filings reveal fund conviction in tech-adjacent like TTM Technologies ($45.8M Emerald), NVIDIA/Apple (Paradiem), MSFT/AMZN (Camden). Portfolio-level: improving liquidity (Snow Lake cash +606% YoY) amid losses, neutral appointments (Block CAO, Ducommun director), setting up catalysts in tenders/AGMs.

15 high priority 13 medium 28 total filings
· daily

S&P 500 Energy Sector SEC Filings — May 04, 2026

S&P 500 Energy sector filings reveal mixed Q1 2026 performance, with ExxonMobil (XOM) posting 2.4% YoY revenue growth to $85.1B but a sharp 45.8% YoY net income drop to $4.2B due to higher costs and Energy Products losses, contrasting Hess Midstream's (HESM) stable results with Adjusted EBITDA up 2.6% YoY to $299.8M. Major M&A advances with Devon Energy (DVN) and Coterra (CTRA) merger overwhelmingly approved (98-99% votes), set to close ~May 7, enhancing scale in E&P. Leadership transitions signal continuity: XOM elects new Chief Accounting Officer effective July 1, Occidental (OXY) names COO Richard Jackson as CEO from June 1. Capital returns remain robust, with XOM deploying $9.2B on buybacks/dividends, HESM repurchasing $60M units/shares and hiking distributions 2.4% to $0.7792/share. Williams Companies (WMB) shows strong governance via AGM approvals (91-99% support). Non-energy filings like 13Fs and SPACs add neutral context but no sector impact. Overall, cost pressures challenge integrateds/midstream, but M&A catalysts and returns support resilience.

8 high priority 5 medium 13 total filings
· daily

Nasdaq 100 Stocks SEC Filings — May 01, 2026

Across 30 filings from NASDAQ-100 related entities, Q1 2026 results reveal resilient revenue growth averaging 8.2% YoY (Apple +16.5%, Atmus +14.7%, Iradimed +12.6-13%, Verizon +2.9%, Shenandoah +4.8%), but profitability mixed with compressions in 6/12 reporters (Smurfit operating profit -54.2%, Shenandoah net loss widened to $15.8M from $9.1M, TXNM earnings -58.1%). Capital allocation remains shareholder-friendly with $36B Apple buybacks, $2.5B Verizon repurchases, steady dividends (Kennametal $0.20, Iradimed $0.20, Atmus $0.055), and gains from divestitures (First Community $10M pre-tax). M&A activity accelerates (Verizon $9.48B acquisitions boosting goodwill +34%, Atmus Koch Filter adding $456M net assets, TXNM Blackstone deal pending H2 2026 at $61.25/share). Risks emerge from accounting errors (Ducommun restatements overstating net income $9.8M FY2024), workforce cuts (Shenandoah 10% RIF saving $12.3M annually from 2027), and low AGM participation (Aditxt 34.17%). Forward guidance stable (Iradimed FY2026 rev $91-96M, Atmus $1.945-2.015B, Shenandoah $370-377M), signaling sector resilience amid macro pressures. Portfolio-level trend: Industrials/tech outperform telecom/energy on growth, with buybacks signaling management conviction.

13 high priority 17 medium 30 total filings
· daily

S&P 500 Financials Sector SEC Filings — May 01, 2026

The 50 filings from S&P 500 Financials and adjacent sectors reveal mixed Q1 2026 results, with average revenue growth of +11% YoY across 25 reporting companies (e.g., Ares +strong fundraising, BNY Mellon +13%), but frequent margin compression (-100 bps avg in 8/15 industrials/financial services) and negative cash flows in 12 firms (e.g., Cinemark $(20.4)M op CF, Ryan Specialty $(167)M). Asset managers excelled with AUM/AUC/A growth averaging 15% YoY (Ares +18%, BNY +12% AUC/A, TPG $306B), driving fee income surges (+25% Ares), while banks/insurers showed resilient capital returns via dividends/buybacks totaling >$1B (News Corp $1B program, Verizon $2.5B repurchases). M&A activity heated up with 6 deals (UWM revised Two Harbors offer at $12 cash/2.33x, Esperion 58% premium acquisition, Stock Yards Field & Main), signaling consolidation. Capital allocation favors shareholders (18 firms: div hikes Piper +14%, buybacks Ryan $40M), but debt rises (Shenandoah +10%, Dream Finders +17% QoQ) and outflows (Virtus $(8.4)B) flag caution. Guidance mixed: 7 raises (Newell flat to +2%, Piper low-double digits), 3 cuts (Fulgent Non-GAAP loss to $(1.59)). Portfolio implication: Overweight asset managers/financial services on AUM tailwinds, underweight cyclicals amid cash burn; monitor Q2 catalysts like div record dates in June.

15 high priority 35 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — May 01, 2026

Across 50 recent SEC filings from the S&P 500 Consumer Staples stream and related sectors, Q1 2026 results reveal mixed performance with average revenue growth of +4% YoY in staples-focused filers (e.g., Estee Lauder +5%, Colgate +8.4%, Newell -1.1%), driven by premium categories like fragrance and Latin America but offset by North America weakness and core sales declines. Margin trends show resilience with expansions in 4/7 key staples reporters (Estee Lauder +360 bps adjusted, Newell gross +100 bps) amid restructuring benefits, though Colgate saw -20 bps gross compression. Major M&A activity includes McCormick's $2B term loan for Unilever foods acquisition (Apollo), signaling consolidation in flavors/foods, while Estee Lauder pursues bolt-ons in India/UK skincare. Capital allocation leans shareholder-friendly with buybacks (Colgate $306M, Asbury $157M) and dividends (TPG $0.59, Perella $0.07), but cash burns in some (Newell -$233M op CF). Forward guidance largely positive (Estee FY26 organic high-end raise, Newell FY26 flat-2% sales), building a catalyst calendar into Q2 earnings. Broader patterns flag staples outperformance vs. autos/telecom declines, with institutional 13Fs showing staples exposure via ETFs/dividend funds. Actionable implication: Favor premium staples with China exposure and M&A; monitor NA softness.

21 high priority 29 medium 50 total filings